PICO Portalanswers from OpenAlex & ORCID
David Vicente
ResearcherPublications, citations & collaboration network
David Vicente is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does David Vicente have?
PICO Portalindexed works
David Vicente has 104 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David Vicente have?
PICO Portalcitation count
David Vicente has 17,824 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of David Vicente?
PICO Portalh-index
David Vicente has an h-index of 33 in OpenAlex.
What is the i10-index of David Vicente?
PICO Portali10-index
David Vicente has an i10-index of 52 in OpenAlex.
What is the ORCID of David Vicente?
PICO Portalorcid
The ORCID for David Vicente is on the source record.
What is the OpenAlex record for David Vicente?
PICO Portalopenalex
The OpenAlex for David Vicente is on the source record.
What are the most-cited papers on David Vicente?
PICO Portalmost cited works
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz‐Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Bárbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp, Jerónimo Rafael Rodríguez‐Cid, Jonathan Wilson, Shunichi Sugawara, Terufumi Kato, Ki Hyeong Lee, Ying Cheng, Silvia Novello, Balázs Halmos, Xiaodong Li, Gregory M. Lubiniecki, Bilal Piperdi, Dariusz M. Kowalski
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz‐Ares, David Vicente, Ali Tafreshi, Andrew Robinson, Héctor Soto Parrà, Julien Mazières, Bárbara Hermes, İrfan Çiçin, Balazs Medgyasszay, Jerónimo Rafael Rodríguez‐Cid, Isamu Okamoto, Sung-Sook Lee, Rodryg Ramlau, Vladimir Vladimirov, Ying Cheng, Xuan Deng, Ying Zhang, Tuba Öcek Baş, Bilal Piperdi, Balázs Halmos
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
Silvia Novello, Dariusz M. Kowalski, Alexander Luft, Mahmut Gümüş, David Vicente, Julien Mazières, Jerónimo Rafael Rodríguez‐Cid, Ali Tafreshi, Ying Cheng, Ki Hyeong Lee, Alexander Golf, Shunichi Sugawara, Andrew Robinson, Balázs Halmos, Erin Jensen, Paul Schwarzenberger, M. Catherine Pietanza, Luis Paz‐Ares
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Corinne Faivre‐Finn, David Vicente, Takayasu Kurata, David Planchard, Luis Paz‐Ares, Johan Vansteenkiste, David R. Spigel, Marina Chiara Garassino, Martin Reck, Suresh Senan, Jarushka Naidoo, Andreas Rimner, Yi‐Long Wu, Jhanelle E. Gray, Mustafa Özgüroğlu, Ki Hyeong Lee, Byoung Chul Cho, Terufumi Kato, Maike de Wit, Michael Newton, Lu Wang, Piruntha Thiyagarajah, Scott Antonia